Literature DB >> 32444912

Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases.

Jeremy D Kratz1, Noelle K LoConte2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32444912     DOI： 10.1245/s10434-020-08629-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

Authors:  Jean-Yves Douillard; Kelly S Oliner; Salvatore Siena; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; Gyorgy Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean Luc Canon; Mark Rother; Richard Williams; Alan Rong; Jeffrey Wiezorek; Roger Sidhu; Scott D Patterson
Journal:  N Engl J Med       Date:  2013-09-12       Impact factor: 91.245

2.  Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

Authors:  G Folprecht; T Gruenberger; W Bechstein; H-R Raab; J Weitz; F Lordick; J T Hartmann; J Stoehlmacher-Williams; H Lang; T Trarbach; T Liersch; D Ockert; D Jaeger; U Steger; T Suedhoff; A Rentsch; C-H Köhne
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

3.  Results of R0 resection for colorectal liver metastases associated with extrahepatic disease.

Authors:  Dominique Elias; Lucas Sideris; Marc Pocard; Jean-Francois Ouellet; Valérie Boige; Philippe Lasser; Jean-Pierre Pignon; Michel Ducreux
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

4.  Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Authors:  John H Strickler; Jonathan M Loree; Leanne G Ahronian; Aparna R Parikh; Donna Niedzwiecki; Allan Andresson Lima Pereira; Matthew McKinney; W Michael Korn; Chloe E Atreya; Kimberly C Banks; Rebecca J Nagy; Funda Meric-Bernstam; Richard B Lanman; AmirAli Talasaz; Igor F Tsigelny; Ryan B Corcoran; Scott Kopetz
Journal:  Cancer Discov       Date:  2017-12-01       Impact factor: 39.397

5.  Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.

Authors:  John A Bridgewater; Siân A Pugh; Tom Maishman; Zina Eminton; Jane Mellor; Amy Whitehead; Louise Stanton; Michael Radford; Andrea Corkhill; Gareth O Griffiths; Stephen Falk; Juan W Valle; Derek O'Reilly; Ajith K Siriwardena; Joanne Hornbuckle; Myrddin Rees; Timothy J Iveson; Tamas Hickish; O James Garden; David Cunningham; Timothy S Maughan; John N Primrose
Journal:  Lancet Oncol       Date:  2020-01-31       Impact factor: 41.316

6.  Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

Authors:  Chiara Cremolini; Carlotta Antoniotti; Sara Lonardi; Giuseppe Aprile; Francesca Bergamo; Gianluca Masi; Roberta Grande; Giuseppe Tonini; Claudia Mescoli; Giovanni Gerardo Cardellino; Luigi Coltelli; Lisa Salvatore; Domenico Cristiano Corsi; Cristiana Lupi; Donatello Gemma; Monica Ronzoni; Emanuela Dell'Aquila; Federica Marmorino; Francesca Di Fabio; Maria Laura Mancini; Lorenzo Marcucci; Gabriella Fontanini; Vittorina Zagonel; Luca Boni; Alfredo Falcone
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

7.  Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial.

Authors:  Siân Pugh; Raphaële Thiébaut; John Bridgewater; Marie-Lise Grisoni; Karwan Moutasim; Francis Rousseau; Gareth J Thomas; Gareth Griffiths; François Liebaert; John Primrose; Pierre Laurent-Puig
Journal:  Oncotarget       Date:  2017-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.